DexCom (NASDAQ:DXCM), incorporated in 1999 and headquartered in San Diego, California, is a global leader in continuous glucose monitoring (CGM) systems for people with diabetes. The company designs, manufactures and distributes a suite of wearable devices and associated software that enable real-time glucose readings, trend analysis and personalized alerts. DexCom’s product lineup includes sensor and transmitter combinations that communicate wirelessly with receivers and compatible smart devices, providing users and their care teams with actionable insights into glucose levels throughout the day and night.
At the core of DexCom’s offerings is the FDA-approved G6 CGM system, which delivers factory-calibrated data without the need for fingersticks. Building on this platform, DexCom has introduced the G7 system—a smaller, all-in-one sensor and transmitter that offers shorter warm-up times, extended wear and enhanced connectivity. Complementing its hardware, DexCom provides DexCom Clarity, a cloud-based data management platform that aggregates glucose metrics, generates reports and supports remote monitoring through secure data sharing with healthcare professionals and family members.
DexCom operates in more than 80 countries, with direct commercial teams and distribution partnerships across North America, Europe, Asia and the Asia-Pacific region. The company works closely with payers, healthcare providers and diabetes technology partners—such as insulin pump manufacturers—to integrate CGM data into comprehensive diabetes management workflows. Its research and development efforts focus on advancing sensor accuracy, reducing device size and exploring expanded indications for CGM in both type 1 and type 2 diabetes populations.
Under the leadership of President and CEO Kevin Sayer, DexCom has grown from a start-up into a publicly traded innovator in diabetes care, committed to improving patient outcomes through continuous innovation. The executive team and board of directors bring extensive experience in medical devices, regulatory affairs and global commercialization, guiding the company’s mission to empower people to take control of their diabetes through precise, real-time glucose monitoring.
